Denali Therapeutics Inc. (DNLI) · Nov 3, 2026 · Earnings
Beat — Revenue $17.8M vs ~$12.2M consensus
Denali’s Q3 earnings show AVLAYAH commercial momentum well ahead of expectations, while a one-time voucher sale masks continued operating losses.
Denali is moving from a development-stage biotech into its first commercial launch, using AVLAYAH to validate its blood-brain-barrier delivery platform while funding a broad pipeline of investigational programs. The prior quarter had set a third-quarter AVLAYAH revenue expectation of $10 million to $12 million, while published consensus was roughly $12.2 million; the company delivered $17.8 million, making the launch trajectory the clear positive surprise.
AVLAYAH commercialization is materially ahead of the near-term bar. Q3 product revenue reached $17.8 million, up from zero a year earlier and roughly 46% above published consensus; that is stronger evidence of early demand, payer access and launch execution than the market was assuming.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Product revenue (Financial Highlights) | $17.8M (+46%) | $0.0M | $12.2M |
| R&D expense (Financial Highlights) | $106.1M (+4.1%) | $102.0M | |
| SG&A expense (Financial Highlights) | $37.5M (+5.6%) | $35.5M | |
| Operating loss (Financial Highlights) | $126.8M (-7.8%) | $137.4M | |
| Net income (Financial Highlights) | $70.1M | $(126.9)M |
The headline profit is not operating profitability. Denali reported $70.1 million of net income, but the result included a one-time $194.0 million gain from selling a Priority Review Voucher; the underlying business still produced a $126.8 million operating loss. The more useful signal is that revenue is beginning to offset a portion of the ongoing research, development and commercial buildout—not that Denali has reached sustainable earnings.
The pipeline remains on schedule, not newly de-risked. Denali completed enrollment of the COMPASS study at 65 participants, completed the prespecified treatment duration in the zafinofusp study, and retained its 2027 BLA plan; these are execution milestones, but the filing does not add decisive clinical efficacy data or accelerate the stated timeline. The next major proof points remain zafinofusp data and the 2027 readouts across DNL593, DNL628, DNL921 and DNL151. 〔0〕
Cash remains substantial, though the launch is still consuming capital. Cash, cash equivalents and marketable securities totaled about $1.01 billion at September 30, 2026, versus roughly $1.10 billion pro forma after the July voucher proceeds discussed in the prior quarter. The balance sheet supports continued pipeline investment, but the rise in R&D and launch-related SG&A shows that commercial revenue has not yet changed the company’s cash-burn profile.
Bottom line: This is a genuine commercial execution beat: AVLAYAH is ramping faster than expected and strengthens Denali’s platform story. The quarter is not a profitability inflection, and the pipeline remains dependent on 2027 clinical and regulatory milestones rather than new evidence in this filing.
Zafinofusp Phase 1/2 data and BLA submission in 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!